{"title":"身体畸形障碍。","authors":"J. Cotterill","doi":"10.1097/01.nme.0000550562.49125.31","DOIUrl":null,"url":null,"abstract":"Body dysmorphic disorder is one of the most difficult conditions to manage but a significant proportion of patients do respond to selective serotonin reuptake inhibitors. This group of drugs has helped to revolutionize the treatment of this common but disabling disorder of perceived body ugliness. The condition may affect up to 1% of the population in the United States. Patients often show obsessional features, and depression is common. Ever present is a risk of suicide in these patients.","PeriodicalId":94312,"journal":{"name":"Dermatologic clinics","volume":"85 1","pages":"457-63"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":"{\"title\":\"Body dysmorphic disorder.\",\"authors\":\"J. Cotterill\",\"doi\":\"10.1097/01.nme.0000550562.49125.31\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Body dysmorphic disorder is one of the most difficult conditions to manage but a significant proportion of patients do respond to selective serotonin reuptake inhibitors. This group of drugs has helped to revolutionize the treatment of this common but disabling disorder of perceived body ugliness. The condition may affect up to 1% of the population in the United States. Patients often show obsessional features, and depression is common. Ever present is a risk of suicide in these patients.\",\"PeriodicalId\":94312,\"journal\":{\"name\":\"Dermatologic clinics\",\"volume\":\"85 1\",\"pages\":\"457-63\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologic clinics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.nme.0000550562.49125.31\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic clinics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.nme.0000550562.49125.31","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Body dysmorphic disorder is one of the most difficult conditions to manage but a significant proportion of patients do respond to selective serotonin reuptake inhibitors. This group of drugs has helped to revolutionize the treatment of this common but disabling disorder of perceived body ugliness. The condition may affect up to 1% of the population in the United States. Patients often show obsessional features, and depression is common. Ever present is a risk of suicide in these patients.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
